Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that company
management will participate in the H.C. Wainwright BioConnect 2021
Conference to be held virtually January 11-14, 2021.
The fireside chat will be available on-demand through the H.C.
Wainwright conference portal, beginning at 6:00 AM ET on Monday,
January 11, 2021.
A webcast will also be available on the “Events and
Presentations” page in the “Investors & Media” section of
Aptinyx’s website at https://ir.aptinyx.com and will be archived on
Aptinyx’s website for 30 days following the event.
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment associated with Parkinson’s disease. Aptinyx is also
advancing additional compounds from its proprietary discovery
platform, which continues to generate a rich and diverse pipeline
of small-molecule NMDA receptor modulators with the potential to
treat an array of neurologic disorders. For more information, visit
Source: Aptinyx Inc.
version on businesswire.com: https://www.businesswire.com/news/home/20210105005274/en/
Investor and Media Contact: Nick Smith Aptinyx Inc.
firstname.lastname@example.org or email@example.com 847-871-0377